Loss of phosphoinositide 3-kinase P110γ is protective in the acute phase but detrimental in the resolution phase of hapten-induced colitis.

Abstract:

BACKGROUND:Pharmacologic inhibition or genetic ablation of phosphoinositide 3-kinase gamma (PI3Kγ) has been shown to be protective against experimental colitis. However, the role of PI3Kγ in the resolution phase of colitis remains unexplored. In this study, we assess the effects of genetic knockout of PI3Kγ on the induction and resolution of colitis induced by the hapten trinitrobenzene sulfonic acid (TNBS). METHODS:Colitis was induced in wild-type C57/Bl6 or PI3Kγ-/- mice by intrarectal administration of 2.5 mg of TNBS in 50% ethanol. Body weights were monitored daily, and colon tissues were collected at days 3, 7, or 14 after treatment, and colitis was assessed using disease activity and histologic damage scores, measurement of tissue myeloperoxidase and neutrophil infiltration, and local cytokine production. RESULTS:Mice lacking PI3Kγ were significantly protected from disease during the acute phase (day 3) of TNBS colitis. However, PI3Kγ-/- mice have difficulty resolving acute inflammation because they failed to restore lost weight and had significantly elevated histologic damage scores and tissue myeloperoxidase levels at days 7 and 14 after TNBS administration compared with wild-type controls. This phenomenon was dependent on presensitization with TNBS and seems to involve an inability to clear invading bacteria, resulting in the generation of a persistent inflammatory cytokine response. CONCLUSIONS:This study confirms that PI3Kγ plays a role in the induction of colitis. However, PI3Kγ is also required for the resolution of intestinal damage following acute inflammation. This must be taken into consideration before the inhibition of PI3Kγ can be used as a treatment for disorders such as inflammatory bowel disease.

journal_name

Inflamm Bowel Dis

authors

Prescott D,Atkinson B,Döring A,Brown S,Petri B,McKay DM,Waterhouse CC

doi

10.1097/MIB.0b013e31827feb84

subject

Has Abstract

pub_date

2013-03-01 00:00:00

pages

489-500

issue

3

eissn

1078-0998

issn

1536-4844

journal_volume

19

pub_type

杂志文章
  • Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing.

    abstract:BACKGROUND:Granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy is effective in treating some Crohn's disease (CD) patients and protects mice from colitis induced by dextran sulfate sodium (DSS) administration. However, its mechanisms of action remain elusive. We hypothesized that GM-CSF affects intestinal...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21072

    authors: Bernasconi E,Favre L,Maillard MH,Bachmann D,Pythoud C,Bouzourene H,Croze E,Velichko S,Parkinson J,Michetti P,Velin D

    更新日期:2010-03-01 00:00:00

  • Roles of CD1d-restricted NKT cells in the intestine.

    abstract::Natural killer T (NKT) cells are a subset of lymphocytes that express cell surface molecules of both conventional T cells and natural killer cells and share the features of both innate and adaptive immune cells. NKT cells have been proposed to make both protective and pathogenic contributions to inflammatory bowel dis...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.20164

    authors: van Dieren JM,van der Woude CJ,Kuipers EJ,Escher JC,Samsom JN,Blumberg RS,Nieuwenhuis EE

    更新日期:2007-09-01 00:00:00

  • Risk factors and outcome of PCR-detected Clostridium difficile infection in ileal pouch patients.

    abstract:BACKGROUND:The clinical implication of Clostridium difficile infection (CDI) in patients with ileal pouch-anal anastomosis (IPAA) for underlying inflammatory bowel disease (IBD) has not been well studied. This study was designed to investigate the cumulative incidence, risk factors, and outcome of CDI in patients with ...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章

    doi:10.1097/MIB.0b013e318280fcb9

    authors: Li Y,Qian J,Queener E,Shen B

    更新日期:2013-02-01 00:00:00

  • Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.

    abstract:BACKGROUND:PYRAMID was an international multicenter, noninterventional, postmarketing registry assessing long-term safety and effectiveness of adalimumab (Humira), as used in routine clinical practice. METHODS:Adult patients with moderately to severely active Crohn's disease with or without prior adalimumab experience...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1093/ibd/izz008

    authors: Loftus EV,Reinisch W,Panaccione R,Berg S,Alperovich G,Bereswill M,Kalabic J,Petersson J,Thakkar R,Robinson AM,D'Haens G

    更新日期:2019-08-20 00:00:00

  • Outcomes of Endoscopic Therapy for Luminal Strictures in Crohn's Disease.

    abstract:Backgrounds:We sought to describe the outcomes of endoscopic therapy of luminal strictures in patients with Crohn's disease (CD) at a large tertiary referral center. Methods:All patients who had undergone endoscopic dilation of CD strictures between January 1, 1990 and November 30, 2013 were identified. Demographics, ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy049

    authors: Shivashankar R,Edakkanambeth Varayil J,Scott Harmsen W,Faubion WA,Wong Kee Song LM,Bruining DH,Schroeder KW,Kisiel J,Loftus EV Jr,Coelho Prabhu N

    更新日期:2018-06-08 00:00:00

  • VSL#3 Probiotic Stimulates T-cell Protein Tyrosine Phosphatase-mediated Recovery of IFN-γ-induced Intestinal Epithelial Barrier Defects.

    abstract:BACKGROUND:VSL#3 is a probiotic compound that has been used in the treatment of inflammatory bowel disease. T-cell protein tyrosine phosphatase (TCPTP) is the protein product of the inflammatory bowel disease candidate gene, PTPN2, and we have previously shown that it protects epithelial barrier function. The aim of th...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000954

    authors: Krishnan M,Penrose HM,Shah NN,Marchelletta RR,McCole DF

    更新日期:2016-12-01 00:00:00

  • Inhibition of Interleukin-10 Signaling Induces Microbiota-dependent Chronic Colitis in Apolipoprotein E Deficient Mice.

    abstract:BACKGROUND:Apolipoprotein E (ApoE) mediates potent antiinflammatory and immunomodulatory properties in addition to its roles in regulating cholesterol transport and metabolism. However, its role in the intestine, specifically during inflammation, is largely unknown. METHODS:Mice (C57BL/6 or ApoE-deficient [ApoE-KO] mi...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000699

    authors: Singh V,Kumar M,San Yeoh B,Xiao X,Saha P,Kennett MJ,Vijay-Kumar M

    更新日期:2016-04-01 00:00:00

  • Multidimensional Impact of Mediterranean Diet on IBD Patients.

    abstract:BACKGROUND & AIMS:Malnutrition with the accumulation of fat tissue and nonalcoholic fatty liver disease (NAFLD) are conditions associated with inflammatory bowel disease (IBD). Visceral fat and NAFLD-related liver dysfunction can both worsen intestinal inflammation. Because the Mediterranean diet (Md) has been shown to...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izaa097

    authors: Chicco F,Magrì S,Cingolani A,Paduano D,Pesenti M,Zara F,Tumbarello F,Urru E,Melis A,Casula L,Fantini MC,Usai P

    更新日期:2021-01-01 00:00:00

  • The case for using 5-aminosalicyclates in Crohn's disease: pro.

    abstract::Mesalamine has a well-established role in the management of ulcerative colitis. However, its role in the management of Crohn's disease (CD) is less clear. Studies evaluating its therapeutic value in CD have produced both positive and negative results. Meta-analyses have not clarified the situation, possibly because th...

    journal_title:Inflammatory bowel diseases

    pub_type: 评论,社论

    doi:10.1097/01.mib.0000160743.24772.69

    authors: Hanauer SB

    更新日期:2005-06-01 00:00:00

  • Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics.

    abstract:BACKGROUND:The cumulative incidence of colectomy and the impact of 5-aminosalicylates (5-ASA), azathioprine, and antitumor necrosis factor (TNF) treatment on the long-term need for surgery are unknown in ulcerative colitis (UC) in the era of biologics. METHODS:This was an observational study of a referral center cohor...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21932

    authors: Williet N,Pillot C,Oussalah A,Billioud V,Chevaux JB,Bresler L,Bigard MA,Gueant JL,Peyrin-Biroulet L

    更新日期:2012-09-01 00:00:00

  • Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO survey.

    abstract:BACKGROUND:Adherence to treatment is a key condition in preventing relapses in inflammatory bowel disease (IBD). The aims of this study were specifically to study socioeconomic and psychological factors and adherence to treatment in a large cohort of patients. METHODS:A questionnaire concerning demographic, clinical, ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21482

    authors: Nahon S,Lahmek P,Saas C,Durance C,Olympie A,Lesgourgues B,Gendre JP

    更新日期:2011-06-01 00:00:00

  • Crohn's disease-associated Escherichia coli LF82 aggravates colitis in injured mouse colon via signaling by flagellin.

    abstract:BACKGROUND:Ileal lesions in Crohn's disease patients are colonized by pathogenic adherent-invasive Escherichia coli (AIEC) that harbor various virulence factors involved in adhesion to and invasion of intestinal epithelial cultured cells. We investigated in a mouse model of colonic inflammation the behavior of virulent...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20423

    authors: Carvalho FA,Barnich N,Sauvanet P,Darcha C,Gelot A,Darfeuille-Michaud A

    更新日期:2008-08-01 00:00:00

  • Connecting Families: A Pediatric IBD Center's Development and Implementation of a Volunteer Parent Mentor Program.

    abstract::It is estimated that over one million people are living with inflammatory bowel disease (IBD) in the United States and that 20-25% of those are children. Pediatric IBD presents with more severe and extensive disease when compared to adults. As with all pediatric chronic illnesses, the patient as well as their parents ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000733

    authors: Donegan A,Boyle B,Crandall W,Dotson JL,Lemont C,Moon T,Kim SC

    更新日期:2016-05-01 00:00:00

  • A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.

    abstract:BACKGROUND:Multi-matrix (MMx), a new delivery system for mesalazine, seems to release 5-aminosalicyclic acid (5-ASA) preferentially in the sigmoid colon. This study had 2 objectives: (1) to evaluate the therapeutic response to MMx in patients with active left-sided disease and (2) to gain additional insights as to how ...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/01.mib.0000158386.25660.1e

    authors: Prantera C,Viscido A,Biancone L,Francavilla A,Giglio L,Campieri M

    更新日期:2005-05-01 00:00:00

  • Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease.

    abstract:OBJECTIVES:There is some uncertainty regarding how to best dose and therapeutically monitor 6-mercaptopurine or azathioprine in patients with inflammatory bowel disease. The purpose of this study was to assess the relation between clinical response, 6-mercaptopurine metabolite levels, relative leukopenia, and drug dose...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章

    doi:10.1097/00054725-200407000-00003

    authors: Achkar JP,Stevens T,Easley K,Brzezinski A,Seidner D,Lashner B

    更新日期:2004-07-01 00:00:00

  • Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis.

    abstract:BACKGROUND:The efficacy of anti-tumor necrosis factor monoclonal antibody (anti-TNF mAb) for Crohn's disease (CD) is well established, and anti-interleukin-6 receptor (anti-IL-6R) mAb has also been reported to be effective in CD. It is, however, unclear if the efficacy and mechanisms of both agents are different in CD ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21384

    authors: Terabe F,Fujimoto M,Serada S,Shinzaki S,Iijima H,Tsujii M,Hayashi N,Nomura S,Kawahata H,Jang MH,Miyasaka M,Mihara M,Ohsugi Y,Kishimoto T,Naka T

    更新日期:2011-02-01 00:00:00

  • Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial.

    abstract:BACKGROUND:The PAILOT trial was a randomized controlled trial aimed to evaluate proactive vs reactive therapeutic drug monitoring in children with Crohn's disease (CD) treated with adalimumab. Our aim in this post hoc analysis of the PAILOT trial was to assess the efficacy and safety of adalimumab combination treatment...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz294

    authors: Matar M,Shamir R,Turner D,Broide E,Weiss B,Ledder O,Guz-Mark A,Rinawi F,Cohen S,Topf-Olivestone C,Shaoul R,Yerushalmi B,Ben-Horin S,Assa A

    更新日期:2020-10-23 00:00:00

  • Control of NOD2 and Rip2-dependent innate immune activation by GEF-H1.

    abstract:BACKGROUND:Genetic variants of nucleotide-binding oligomerization domain 2 (NOD2) lead to aberrant microbial recognition and can cause chronic inflammatory diseases in patients with Crohn's disease (CD). METHODS:We utilized gene-specific siRNA mediated knockdown and expression of guanine nucleotide exchange factor H1 ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21851

    authors: Zhao Y,Alonso C,Ballester I,Song JH,Chang SY,Guleng B,Arihiro S,Murray PJ,Xavier R,Kobayashi KS,Reinecker HC

    更新日期:2012-04-01 00:00:00

  • Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study.

    abstract:BACKGROUND:Mesalazine preparations are widely used to treat mild to moderately severe ulcerative colitis (UC). We compared once-daily administration of oral mesalazine in patients with quiescent UC with the established 3-times-daily prescription, assessing the efficacy and safety of each method in maintaining remission...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/MIB.0b013e318286fa3d

    authors: Watanabe M,Hanai H,Nishino H,Yokoyama T,Terada T,Suzuki Y

    更新日期:2013-07-01 00:00:00

  • Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides.

    abstract:BACKGROUND:Differentiating ulcerative colitis (UC) from Crohn's colitis (CC) can be difficult and may lead to inaccurate diagnoses in up to 30% of inflammatory bowel disease (IBD) patients. Much of the diagnostic uncertainty arises from the overlap of clinical and histologic features. Matrix-assisted laser desorption/i...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21442

    authors: M'Koma AE,Seeley EH,Washington MK,Schwartz DA,Muldoon RL,Herline AJ,Wise PE,Caprioli RM

    更新日期:2011-04-01 00:00:00

  • Words fail me: the verbal IQ deficit in inflammatory bowel disease and irritable bowel syndrome.

    abstract:BACKGROUND:Many chronic illnesses are accompanied by impaired cognitive functioning. In people with Inflammatory Bowel Disease (IBD), there is some research to suggest a decrement in verbal IQ (VIQ), when compared to people with Irritable Bowel Syndrome (IBS) and healthy controls. Although this is an important finding,...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20837

    authors: Dancey CP,Attree EA,Stuart G,Wilson C,Sonnet A

    更新日期:2009-06-01 00:00:00

  • Enteral feeding therapy for newly diagnosed pediatric Crohn's disease: a double-blind randomized controlled trial with two years follow-up.

    abstract:BACKGROUND:This study compared the efficacy of an elemental formula (EF) to a polymeric formula (PF) in inducing remission for pediatric Crohn's disease (CD). METHODS:Newly diagnosed CD children were randomized to EF or PF for 6 weeks. Change in the Pediatric Crohn's Disease Activity Index (PCDAI), fecal calprotectin,...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/ibd.21690

    authors: Grogan JL,Casson DH,Terry A,Burdge GC,El-Matary W,Dalzell AM

    更新日期:2012-02-01 00:00:00

  • Apical Periodontitis in Patients With Inflammatory Bowel Disease: A Puppet Master?

    abstract::Focal infection theory posits that periodontal pathobionts play a causal role in initiating or exacerbating diseases. Periodontal disease is a common inflammatory, multifactorial disease of the periodontal tissues. The main factor for inflammation is mature dental plaque with the presence of pathogens in the microbial...

    journal_title:Inflammatory bowel diseases

    pub_type: 评论,社论

    doi:10.1093/ibd/izz129

    authors: Barta Z

    更新日期:2020-01-06 00:00:00

  • Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH.

    abstract:BACKGROUND:There has been a dramatic increase in investigations on the potential mechanistic role of the intestinal microbiota in various diseases and factors modulating intestinal microbial composition. We recently reported on intestinal microbial shifts after smoking cessation in humans. In this study, we aimed to co...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000129

    authors: Biedermann L,Brülisauer K,Zeitz J,Frei P,Scharl M,Vavricka SR,Fried M,Loessner MJ,Rogler G,Schuppler M

    更新日期:2014-09-01 00:00:00

  • The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis.

    abstract:Background:Clinical trials investigating the use of cannabinoid drugs for the treatment of intestinal inflammation are anticipated secondary to preclinical literature demonstrating efficacy in reducing inflammation. Methods:We systematically reviewed publications on the benefit of drugs targeting the endo-cannabinoid ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,meta分析

    doi:10.1093/ibd/izy014

    authors: Couch DG,Maudslay H,Doleman B,Lund JN,O'Sullivan SE

    更新日期:2018-03-19 00:00:00

  • Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD.

    abstract::Crohn's disease and ulcerative colitis are quite often complicated with manifestations in extraintestinal organs like joints, eye, and skin. Although the etiopathogenesis of these nonmucosal complications remains unsettled, they all share the characteristic feature of inappropriate leukocyte recruitment in nonlymphati...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.3780040210

    authors: Salmi M,Jalkanen S

    更新日期:1998-05-01 00:00:00

  • Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis.

    abstract:BACKGROUND:Recently, granulocyte and monocyte adsorption apheresis (GCAP) has been shown to be safe and effective for active ulcerative colitis (UC). We analyzed the safety and efficacy of GCAP (G-1 Adacolumn) in patients with steroid-refractory and -dependent UC. G-1 Adacolumn is filled with cellulose acetate carriers...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章

    doi:10.1097/00054725-200405000-00012

    authors: Naganuma M,Funakoshi S,Sakuraba A,Takagi H,Inoue N,Ogata H,Iwao Y,Ishi H,Hibi T

    更新日期:2004-05-01 00:00:00

  • Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine.

    abstract::Diagnostics of inflammatory bowel diseases (IBDs) currently relies on a combination of biological and morphological tests. The current method of diagnostic remains a critical challenge for physicians in part due to their invasiveness and also for their limitations in term of diagnosis, prognosis, disease activity and ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000000444

    authors: Viennois E,Zhao Y,Merlin D

    更新日期:2015-10-01 00:00:00

  • Hospital Admissions, Biological Therapy, and Surgery in Familial and Sporadic Cases of Inflammatory Bowel Disease: A Population-Based Cohort Study 1977-2011.

    abstract:BACKGROUND:Easily accessible predictors of disease course in inflammatory bowel disease (IBD) are scarce, and it remains largely unknown whether a family history of IBD predicts the course of Crohn's disease (CD) and ulcerative colitis (UC). We aimed to compare the course of disease in familial and sporadic cases of IB...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000545

    authors: Trier Moller F,Andersen V,Andersson M,Jess T

    更新日期:2015-12-01 00:00:00

  • A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.

    abstract:BACKGROUND:Unlike other anti-tumor necrosis factor alpha antibodies, golimumab does not deliver on its promise of effectiveness for treating patients with ulcerative colitis. We investigated the value of therapeutic drug monitoring for optimizing golimumab therapy. METHODS:We analyzed the golimumab pharmacokinetics da...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz144

    authors: Dreesen E,Kantasiripitak W,Detrez I,Stefanović S,Vermeire S,Ferrante M,Bouillon T,Drobne D,Gils A

    更新日期:2020-03-04 00:00:00